Hester Biosciences has informed that the Board of Directors at the meeting held on 11 March 2026, and on the recommendations of the Audit Committee of the Board, considered and approved the Divestment of 43.81% equity shareholding out of total 54.81% in its subsidiary, Texas Lifesciences (TLPL), by way of transfer/sale of shares to the existing promoter shareholders of the TLPL. TLPL is not material subsidiary of the Company. TLPL will ceased to be the subsidiary of the Company upon completion share transfer transaction as above. The Board Meeting commenced at 10:46 am (IST) and concluded at 11:05 am (IST).
The above information is a part of company’s filings submitted to BSE.
